Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Nature Reviews Cardiology, Published online: 17 January 2020; doi:10.1038/s41569-019-0314-yMany patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease.

Source: Nature Reviews Cardiology - January 16, 2020 Category: Cardiology Authors: Davide Capodanno Deepak L. Bhatt John W. Eikelboom Keith A. A. Fox Tobias Geisler C. Michael Gibson Jose Ramon Gonzalez-Juanatey Stefan James Renato D. Lopes Roxana Mehran Gilles Montalescot Manesh Patel P. Gabriel Steg Robert F. Storey Pascal Vranckx Jef Source Type: research